Pharma news
.jpg/r%5Bwidth%5D=1280&r%5Bheight%5D=720/a838b8f0-1209-11ef-bfe1-7f53b05b4353-Patent%20eligibility%20panel%20(1).webp)
Americas
As Congress considers the Patent Eligibility Restoration Act of 2023, experts from NeoGenomics, Biogen, and Choate Hall & Stewart at LSPN Spring weigh in on its potential effect and the need for further clarification to improve patent eligibility standards. 13 May 2024
.jpg/r%5Bwidth%5D=1280&r%5Bheight%5D=720/a6781c50-0e1b-11ef-a956-87ed2b3f1c3c-IMG_9985%20(1).webp)
Europe
A significant uptake in unitary patents show court is here “in a big way” | Speakers shed light on the UPC's approach to preliminary injunctions and evidence gathering at LSPN Spring in Boston. 9 May 2024
Pharma
Asthma is one of the most common respiratory diseases in the US and the most common chronic disease among children | Israeli pharma giant’s suit comes amid allegations that it keeps life-saving prescriptions treatments artificially high. 7 May 2024
Americas
Two-day event in Boston brings together leading in-house patent counsel | Regeneron, USPTO, the Broad Institute and Novartis among attendees I Agenda includes the UPC, patent strategies, and multijurisdictional patent litigation | Registrations for LSPN Fall now open. 7 May 2024
Pharma
AstraZeneca, GSK and Teva among manufacturers accused of “improper” submission of patents | More than 300 patents targeted in second wave of challenges by Federal Trade Commission | ‘Junk patents’ block competition and ramp up prices unfairly, says FTC chair. 2 May 2024
Careers
Former senior legal advisor at USPTO brings wealth of life sciences experience | Move represents transition back into private practice after two decades. 2 May 2024
Pharma
GSK subsidiary and Exavir Therapeutics end dispute over licensing rights for HIV-drug compounds | Resolution follows allegations that Exavir's actions disrupted ViiV Healthcare's research collaboration with a US university. 25 April 2024
Biotech
Vanda denied opportunity to revive patents for its sleep-disorder drug in dispute against Teva | Decision also rejects revisiting the 2007 case, KSR International v Teleflex, concerning the issue of obviousness in patent claims. 23 April 2024
Careers
Ex-head of Kramer Levin life sciences practice leaves for new firm | 20 years of experience includes numerous multi-billion dollar cases for some of the world’s best-selling drugs. 16 April 2024
Pharma
Judges determine six claims of Novarad’s AR patent to be unpatentable but uphold a further claim | Decision follows unsuccessful challenge by Medivis to another Novarad patent in March. 16 April 2024